Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 10;217(10):e20200140. doi: 10.1084/jem.20200140

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Hong et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 6. — Loss of the ADAMTS5 substrate versican reduces CCM lesion formation. (A) Possible mechanisms by which versican proteolysis may contribute to CCM formation are diagrammed. Versican proteolysis may affect CCM formation through matrix degradation and/or generation of bioactive products. SC, stromal cells. (B) Versican immunostaining of P10 cerebellums from Vcan^+/+ and Vcan^RC/+ mice. Scale bar, 150 µm. Images are representative of two independent experiments. (C) Visual assessment of hindbrains (top) and microCT images (bottom) of CCM lesions in P10 Krit1^ECKO;Vcan^+/+ and littermate Krit1^ECKO;Vcan^RC/+ animals. Scale bars, 1 mm. (D) Blinded microCT quantitation of CCM lesion volume (n = 21–23 from eight litters, Student’s t test). Error bars represent ± SEM; ****, P < 0.0001.